Helios-B三期研究新数据显示:Vutrisiran治疗ATTR-CM患者胃肠道不良事件发生率更低

美股速递
Sep 28, 2025

来自Helios-B三期临床研究的最新数据表明,接受Vutrisiran治疗的ATTR-CM(转甲状腺素蛋白心肌淀粉样变性)患者出现胃肠道不良事件的比例显著降低。

这项研究结果为Vutrisiran在治疗ATTR-CM方面的安全性提供了重要证据,特别是在减少患者胃肠道相关副作用方面展现出明显优势。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10